ALDOA alterations are most frequent in invasive breast carcinoma (nearly 40%), primarily driven by amplifications, with significant frequencies also observed in bladder cancer, uterine tumors, and ovarian epithelial tumors. Here, ALDOA is linked to urinary bladder cancer.